BF
SUPN icon

BOK Financial’s Supernus Pharmaceuticals SUPN Stock Holding History

BOK Financial’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,078
Closed -$749K – 1105
2025
Q4 		$749K Sell
15,078
-74
-0.5% -$3.6K 0.01% 471
2025
Q3 		$724K Buy
15,152
+57
+0.4% +$2.29K 0.01% 491
2025
Q2 		$476K Buy
15,095
+894
+6% +$28.7K 0.01% 582
2025
Q1 		$465K Sell
14,201
-345
-2% -$12.2K 0.01% 577
2024
Q4 		$545K Sell
14,546
-2,937
-17% -$103K 0.01% 541
2024
Q3 		$561K Sell
17,483
-10,703
-38% -$334K 0.01% 541
2024
Q2 		$754K Buy
28,186
+20,093
+248% +$582K 0.01% 514
2024
Q1 		$271K Buy
+8,093
New +$241K ﹤0.01% 670

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BOK Financial's SUPN Position: Q1 2026 in Review

BOK Financial sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 15,078 shares — an estimated $749K sold.

BOK Financial first reported a position in SUPN in Q1 2024 and held it in 8 quarters. The position peaked at $754K in Q2 2024. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • BOK Financial reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • BOK Financial sold 15,078 Supernus Pharmaceuticals shares in Q1 2026, an estimated $749K.
  • BOK Financial first reported a position in Supernus Pharmaceuticals in Q1 2024 and held it in 8 quarters.
  • BOK Financial's Supernus Pharmaceuticals position peaked at $754K in Q2 2024.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on BOK Financial's 13F filing for Q1 2026, filed 8 May 2026.